JP2019501208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501208A5 JP2019501208A5 JP2018541089A JP2018541089A JP2019501208A5 JP 2019501208 A5 JP2019501208 A5 JP 2019501208A5 JP 2018541089 A JP2018541089 A JP 2018541089A JP 2018541089 A JP2018541089 A JP 2018541089A JP 2019501208 A5 JP2019501208 A5 JP 2019501208A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- vaccine
- pseudouridine
- thio
- control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022172576A JP2023015151A (ja) | 2015-10-22 | 2022-10-27 | 呼吸器合胞体ウイルスワクチン |
| JP2024227631A JP2025041835A (ja) | 2015-10-22 | 2024-12-24 | 呼吸器合胞体ウイルスワクチン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245208P | 2015-10-22 | 2015-10-22 | |
| US201562245031P | 2015-10-22 | 2015-10-22 | |
| US62/245,031 | 2015-10-22 | ||
| US62/245,208 | 2015-10-22 | ||
| US201562247563P | 2015-10-28 | 2015-10-28 | |
| US62/247,563 | 2015-10-28 | ||
| US201562248250P | 2015-10-29 | 2015-10-29 | |
| US62/248,250 | 2015-10-29 | ||
| PCT/US2016/058321 WO2017070622A1 (en) | 2015-10-22 | 2016-10-21 | Respiratory syncytial virus vaccine |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172576A Division JP2023015151A (ja) | 2015-10-22 | 2022-10-27 | 呼吸器合胞体ウイルスワクチン |
| JP2024227631A Division JP2025041835A (ja) | 2015-10-22 | 2024-12-24 | 呼吸器合胞体ウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501208A JP2019501208A (ja) | 2019-01-17 |
| JP2019501208A5 true JP2019501208A5 (enExample) | 2019-12-05 |
| JP7687767B2 JP7687767B2 (ja) | 2025-06-03 |
Family
ID=58558153
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541089A Active JP7687767B2 (ja) | 2015-10-22 | 2016-10-21 | 呼吸器合胞体ウイルスワクチン |
| JP2022172576A Pending JP2023015151A (ja) | 2015-10-22 | 2022-10-27 | 呼吸器合胞体ウイルスワクチン |
| JP2024227631A Pending JP2025041835A (ja) | 2015-10-22 | 2024-12-24 | 呼吸器合胞体ウイルスワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172576A Pending JP2023015151A (ja) | 2015-10-22 | 2022-10-27 | 呼吸器合胞体ウイルスワクチン |
| JP2024227631A Pending JP2025041835A (ja) | 2015-10-22 | 2024-12-24 | 呼吸器合胞体ウイルスワクチン |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20180271970A1 (enExample) |
| EP (1) | EP3365008A4 (enExample) |
| JP (3) | JP7687767B2 (enExample) |
| KR (1) | KR20180096592A (enExample) |
| CN (1) | CN108472354A (enExample) |
| AU (1) | AU2016341311B2 (enExample) |
| BR (1) | BR112018008102A2 (enExample) |
| CA (1) | CA3002820A1 (enExample) |
| CL (1) | CL2018001053A1 (enExample) |
| CO (1) | CO2018005229A2 (enExample) |
| EA (1) | EA201891000A1 (enExample) |
| IL (1) | IL258831A (enExample) |
| MA (1) | MA46317A (enExample) |
| MX (1) | MX2018004917A (enExample) |
| PE (1) | PE20181530A1 (enExample) |
| PH (1) | PH12018500856A1 (enExample) |
| SG (2) | SG11201803363YA (enExample) |
| TN (1) | TN2018000154A1 (enExample) |
| TW (1) | TW201729836A (enExample) |
| WO (1) | WO2017070622A1 (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| EP4631970A3 (en) * | 2016-05-04 | 2026-01-07 | CureVac SE | Nucleic acid molecules and uses thereof |
| CN115837014A (zh) | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| EP3555289A1 (en) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Rna affinity purification |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170260A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| WO2019147749A2 (en) * | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| JP7550648B2 (ja) | 2018-03-19 | 2024-09-13 | クリスパー セラピューティクス アーゲー | 新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用 |
| EP3775174A4 (en) * | 2018-03-30 | 2022-07-06 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (rsv) vaccines |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| BR112021000965A2 (pt) * | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102725189B1 (ko) * | 2018-11-01 | 2024-10-31 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
| CA3121191A1 (en) | 2018-11-28 | 2020-06-04 | Crispr Therapeutics Ag | Optimized mrna encoding cas9 for use in lnps |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| WO2020176524A1 (en) * | 2019-02-28 | 2020-09-03 | Novavax, Inc. | Methods for preventing disease or disorder caused by rsv infection |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| US20220145274A1 (en) | 2019-03-12 | 2022-05-12 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| JP7657727B2 (ja) * | 2019-04-02 | 2025-04-07 | サノフイ | 抗原性多量体呼吸器合胞体ウイルスポリペプチド |
| WO2021061594A1 (en) | 2019-09-27 | 2021-04-01 | Merck Sharp & Dohme Corp. | Method for measuring nucleic acid content in lipid nanoprticles using ultraviolet spectrometry |
| CN115778904B (zh) * | 2019-10-29 | 2025-03-28 | 珠海丽凡达生物技术有限公司 | 一种用于体外转染和体内递送mRNA的制剂 |
| KR20220133911A (ko) * | 2020-01-30 | 2022-10-05 | 모더나티엑스, 인크. | 호흡기 바이러스 면역화 조성물 |
| US12569553B2 (en) | 2020-03-09 | 2026-03-10 | Dynavax Technologies Corporation | Shingles vaccines comprising a TLR9 agonist |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| WO2022006368A2 (en) | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN111973563B (zh) * | 2020-09-02 | 2022-06-28 | 崔海港 | 一种鼠李糖脂冻干粉制剂及其制备方法和应用 |
| WO2022099003A1 (en) * | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4326227A1 (en) | 2021-04-23 | 2024-02-28 | ModernaTX, Inc. | Stabilized formulations |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| MX2023014774A (es) | 2021-06-11 | 2024-01-15 | Bayer Ag | Nuevos sistemas de endonucleasas programables de arn tipo v. |
| EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| EP4453191A1 (en) | 2021-12-23 | 2024-10-30 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN120153078A (zh) * | 2022-10-27 | 2025-06-13 | 辉瑞大药厂 | 编码rsv-f的rna分子及含所述rna分子的疫苗 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| US20260209732A1 (en) | 2022-12-13 | 2026-07-23 | Bayer Aktiengesellschaft | Engineered type v rna programmable endonucleases and their uses |
| AU2023427858A1 (en) | 2023-02-03 | 2025-05-15 | Vernagen, LLC | Respiratory syncytial virus mrna vaccine |
| CN116286672B (zh) * | 2023-02-07 | 2025-01-28 | 金宇保灵生物药品有限公司 | 一种口蹄疫病毒及其应用 |
| CN119137160A (zh) * | 2023-03-02 | 2024-12-13 | 苏州艾博生物科技有限公司 | 呼吸道合胞病毒(rsv)的核酸疫苗 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| EP4680275A1 (en) * | 2023-03-17 | 2026-01-21 | GlaxoSmithKline Biologicals S.A. | Rsv-f-encoding nucleic acids |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024260359A1 (zh) * | 2023-06-20 | 2024-12-26 | 石药集团巨石生物制药有限公司 | 一种抵抗呼吸道合胞病毒的mRNA疫苗及其制备方法 |
| WO2024259624A1 (en) * | 2023-06-21 | 2024-12-26 | Shenzhen Genius Biotech Service Co. Ltd | A modified rsv f protein, a nanoparticle, a composition and a vaccine against respiratory syncytial virus infection |
| EP4736848A1 (en) | 2023-06-28 | 2026-05-06 | Shanghai Regenelead Therapies Co., Ltd. | Pharmaceutical composition containing cationic lipid and use thereof |
| CN119490569A (zh) * | 2023-08-16 | 2025-02-21 | 深圳瑞吉生物科技有限公司 | 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用 |
| CN117487823B (zh) * | 2023-09-28 | 2024-10-29 | 怡道生物科技(苏州)有限公司 | 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用 |
| TW202521691A (zh) | 2023-10-06 | 2025-06-01 | 美商藍岩醫療公司 | 經工程化之v型rna可程式核酸內切酶及其用途 |
| WO2025103414A1 (zh) | 2023-11-14 | 2025-05-22 | 上海瑞宏迪医药有限公司 | 一种脂质纳米粒的制备方法和应用 |
| CN120022355A (zh) * | 2023-11-22 | 2025-05-23 | 长春百克生物科技股份公司 | 一种mRNA疫苗及其应用 |
| CN118480560B (zh) | 2024-07-09 | 2024-11-26 | 北京悦康科创医药科技股份有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| EP1412065A2 (en) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
| CA2462593A1 (en) | 2001-10-03 | 2003-04-10 | Kam W. Leong | Compositions for oral gene therapy and methods of using same |
| AU2003217531A1 (en) | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| WO2006063249A2 (en) | 2004-12-10 | 2006-06-15 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
| KR101288729B1 (ko) | 2005-04-01 | 2013-07-23 | 인터자인 테크놀로지스, 인코포레이티드 | 약물 전달용 중합체성 마이셀 |
| US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| EP2319542B1 (en) | 2006-02-21 | 2018-03-21 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| JP2010502713A (ja) | 2006-09-08 | 2010-01-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液を通る輸送を増強するための組成物および方法 |
| EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
| ATE530169T1 (de) | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| JP2011525180A (ja) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
| AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EA201100765A1 (ru) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| EP2391343B1 (en) * | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
| JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
| WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
| RU2573409C2 (ru) | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
| EP2512459A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME | |
| EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| JP5965844B2 (ja) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
| EP2525815B1 (en) | 2010-01-24 | 2015-02-25 | Novartis AG | Irradiated biodegradable polymer microparticles |
| US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| US20130196948A1 (en) | 2010-06-25 | 2013-08-01 | Massachusetts Insitute Of Technology | Polymers for biomaterials and therapeutics |
| CN103153284B (zh) * | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| FI4005592T3 (fi) * | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| US10487332B2 (en) * | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| EA201390600A1 (ru) | 2010-10-22 | 2013-09-30 | Байнд Терапьютикс, Инк. | Терапевтические наночастицы с сополимерами с большим молекулярным весом |
| AU2011323250B2 (en) | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
| US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
| EP2691078A1 (en) | 2011-03-31 | 2014-02-05 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
| ES2820369T3 (es) | 2011-03-31 | 2021-04-20 | Ingell Tech Holding B V | Composiciones biodegradables adecuadas para liberación controlada |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| RU2014104090A (ru) * | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| US9636410B2 (en) * | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| EP2734184B1 (en) | 2011-07-21 | 2018-03-28 | Croda International Plc | Branched polyether-polyamide block copolymers and methods of making and using the same |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| KR20140067070A (ko) | 2011-08-31 | 2014-06-03 | 말린크로트 엘엘씨 | Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질 |
| WO2013044219A1 (en) | 2011-09-22 | 2013-03-28 | Bind Biosciences | Methods of treating cancers with therapeutic nanoparticles |
| US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
| AU2012325997C1 (en) | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| ES2923757T3 (es) * | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| US9415020B2 (en) | 2012-01-19 | 2016-08-16 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| EP2809702B1 (en) | 2012-02-03 | 2017-12-20 | Rutgers, The State University of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
| WO2013120052A1 (en) | 2012-02-10 | 2013-08-15 | E. I. Du Pont De Nemours And Company | Preparation, purification and use of high-x diblock copolymers |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| US20150366997A1 (en) * | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
| US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP4421177A3 (en) * | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| EP3932947A1 (en) * | 2013-03-14 | 2022-01-05 | Translate Bio MA, Inc. | Methods and compositions for delivering mrna coded antibodies |
| WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| ES2967701T3 (es) * | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| WO2015013551A1 (en) * | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| BR112016003361A2 (pt) * | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
-
2016
- 2016-10-21 US US15/767,613 patent/US20180271970A1/en not_active Abandoned
- 2016-10-21 WO PCT/US2016/058321 patent/WO2017070622A1/en not_active Ceased
- 2016-10-21 SG SG11201803363YA patent/SG11201803363YA/en unknown
- 2016-10-21 MA MA046317A patent/MA46317A/fr unknown
- 2016-10-21 TN TNP/2018/000154A patent/TN2018000154A1/en unknown
- 2016-10-21 PE PE2018000599A patent/PE20181530A1/es unknown
- 2016-10-21 KR KR1020187014339A patent/KR20180096592A/ko not_active Withdrawn
- 2016-10-21 TW TW105134193A patent/TW201729836A/zh unknown
- 2016-10-21 MX MX2018004917A patent/MX2018004917A/es unknown
- 2016-10-21 CN CN201680075062.6A patent/CN108472354A/zh active Pending
- 2016-10-21 CA CA3002820A patent/CA3002820A1/en active Pending
- 2016-10-21 JP JP2018541089A patent/JP7687767B2/ja active Active
- 2016-10-21 BR BR112018008102A patent/BR112018008102A2/pt not_active Application Discontinuation
- 2016-10-21 AU AU2016341311A patent/AU2016341311B2/en not_active Expired - Fee Related
- 2016-10-21 EA EA201891000A patent/EA201891000A1/ru unknown
- 2016-10-21 SG SG10201914006UA patent/SG10201914006UA/en unknown
- 2016-10-21 EP EP16858402.7A patent/EP3365008A4/en active Pending
-
2018
- 2018-04-20 CL CL2018001053A patent/CL2018001053A1/es unknown
- 2018-04-20 PH PH12018500856A patent/PH12018500856A1/en unknown
- 2018-04-22 IL IL258831A patent/IL258831A/en unknown
- 2018-05-18 CO CONC2018/0005229A patent/CO2018005229A2/es unknown
-
2022
- 2022-10-27 JP JP2022172576A patent/JP2023015151A/ja active Pending
-
2023
- 2023-05-10 US US18/314,980 patent/US20230390379A1/en active Pending
-
2024
- 2024-12-24 JP JP2024227631A patent/JP2025041835A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12240873B2 (en) | Respiratory syncytial virus (RSV) vaccine | |
| JP2023527309A5 (enExample) | ||
| JP2018531996A5 (enExample) | ||
| JP2019535665A5 (enExample) | ||
| JP2021504445A5 (enExample) | ||
| DE202019006199U1 (de) | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung | |
| RU2018118337A (ru) | Вакцина против вируса гриппа широкого спектра действия | |
| US10751407B2 (en) | PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof | |
| WO2014134439A1 (en) | Immunogenic composition for mers coronavirus infection | |
| WO2019092002A1 (en) | Pharmaceutical compositions for treatment or prevention of viral infections | |
| US11274282B2 (en) | Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen | |
| US9676825B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
| IL293666A (en) | Mumps and measles virus immunogens and their use | |
| US12605443B2 (en) | SAR-CoV-2 DNA vaccine and method of administering thereof | |
| Tamming | Enhancing SARS-CoV-2 DNA Vaccines with CD40 Ligand and Lipid Nanoparticle Delivery | |
| EP4593803A2 (en) | Combination exosomal immunogenic compositions and methods | |
| CN120166938A (zh) | SARS-CoV-2免疫原性组合物和方法 | |
| WO2024249651A2 (en) | Sars cov-2 vaccines, associated polynucleotides, and methods of use | |
| CN119264229A (zh) | 基于SARS-CoV-2的不同奥密克戎变异型的S蛋白的疫苗和组合物 | |
| HK40057100A (en) | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof | |
| CN120359299A (zh) | 一种广谱流感mRNA疫苗 | |
| Tachibana et al. | 666. Type-I IFN Signaling Is Required for the Induction of Antigen-Specific CD8+ T Cell Responses by Adenovirus Vector Vaccine in the Gut-Mucosal Compartment | |
| EA041575B1 (ru) | Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения |